APLS240920P30000
- 0.10
- +0.05+100.00%
Apellis Pharmaceuticals Newsroom
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $61
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $39 to $85
Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho
Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Apellis Pharmaceuticals Analyst Ratings
Buy Rating on Apellis Pharmaceuticals Anchored in Syfovre's Market Share Potential Despite EU Setback
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $39
Apellis Pharmaceuticals (APLS) Gets a Hold From Mizuho Securities
Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan
Apellis Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61
Apellis Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $64
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $64
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)
Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Buy Rating Affirmed on Apellis Pharmaceuticals Amid Empaveli's Strong Clinical Outcomes and Market Potential